Multidrug resistance (MDR) is a fundamentally important medical phenomenon that undermines anticancer and anti-infective therapy of cancer or infectious diseases. Researchers of the Max Perutz Labs, a joint venture by the Medical University of Vienna and the University of Vienna, have delineated the molecular mechanism, whereby the human ABCG2 drug transporter drives MDR. The results suggest new therapeutic strategies to prevent MDR by inhibiting the ABCG2 transporter.
Mitosis is the process by which the genetic information encoded on chromosomes is equally distributed to two daughter cells, a fundamental feature of all life on earth. Scientists led by Alexander Dammermann at the Max Perutz Labs, a joint venture of the University of Vienna and the Medical University of Vienna, now examine how centrioles contribute to this process. The findings, published in “Developmental Cell”, help to elucidate the function of these tiny cellular structures in mitosis.
Everyone owning a house knows it: to stay like new it needs cleaning and mending. Similarly cellsconstantly renovate and get rid of unwanted material in a process called autophagy in order to replace itwith new parts. This ensures that the organism stays healthy over the years. Like a house renovation, different contractors are employed with repairs and getting rid of waste, and perfect communication is required between them. An international team of scientists from Berlin and Berkeley led by Sascha Martens from the Max F. Perutz Laboratories, a joint venture University of Vienna and the Medical University of Vienna now describe how this communication between two important factors takes place and thus ensures that autophagy correctly works in the cell.
Cardiovascular Diseases (CVD) lead to atherosclerosis and heart failure and are prevalent age-related illnesses in humans. In a new study, published in the renowned journal JCI, scientists from Roland Foisner’s group at the Max F. Perutz Laboratories of the University of Vienna and the Medical University of Vienna, together with scientists from the Ludwig Boltzmann Cluster for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna and from the BOKU, Vienna describe the molecular mechanism behind CVD in the premature aging disease Hutchinson-Gilford progeria syndrome (HGPS).
The University of Vienna and Medical University of Vienna are extending their successful collaborationwith Max F. Perutz Laboratories. Rectors Heinz W. Engl from the University of Vienna and Markus Müller from MedUni Vienna signed an agreement to extend the Joint Venture until 2025.